Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials.
about
Low dose cytarabine monotherapy for acute myeloid leukaemiaHypomethylating agents for adult patients with acute myeloid leukaemiaHypomethylating agents for adult patients with acute myeloid leukaemiaLow dose cytarabine monotherapy for acute myeloid leukaemiaStem Cell Modeling of Core Binding Factor Acute Myeloid LeukemiaPersonalized Cancer Risk Assessments for Space Radiation ExposuresMonitoring minimal residual disease in acute myeloid leukaemia: a review of the current evolving strategiesRisk factors for relapse after allogeneic transplantation in acute myeloid leukemiaMolecular landscape of acute myeloid leukemia in younger adults and its clinical relevancePerspectives of differentiation therapies of acute myeloid leukemia: the search for the molecular basis of patients' variable responses to 1,25-dihydroxyvitamin d and vitamin d analogsHow I treat pediatric acute myeloid leukemiaEmerging patterns of somatic mutations in cancerGenomics of acute myeloid leukemiaProgress in acute myeloid leukemiaThe prognostic and functional role of microRNAs in acute myeloid leukemiaDo AML patients with DNMT3A exon 23 mutations benefit from idarubicin as compared to daunorubicin? A single center experience.Age-related prognostic impact of different types of DNMT3A mutations in adults with primary cytogenetically normal acute myeloid leukemiaASXL1 exon 12 mutations are frequent in AML with intermediate risk karyotype and are independently associated with an adverse outcome.Prognostic significance of FLT3 internal tandem duplication, nucleophosmin 1, and CEBPA gene mutations for acute myeloid leukemia patients with normal karyotype and younger than 60 years: a systematic review and meta-analysis.Next-generation sequencing of acute myeloid leukemia identifies the significance of TP53, U2AF1, ASXL1, and TET2 mutationsGenomic Classification and Prognosis in Acute Myeloid Leukemia.Targeting the TAM Receptors in LeukemiaLSD1 inhibition: a therapeutic strategy in cancer?The Broad Anti-AML Activity of the CD33/CD3 BiTE Antibody Construct, AMG 330, Is Impacted by Disease Stage and RiskAcute myeloid leukaemia: challenges and real world data from IndiaDevelopment of acute myeloid leukemia in patients with untreated chronic lymphocytic leukemia.Molecular Basis and Targeted Inhibition of CBFβ-SMMHC Acute Myeloid Leukemia.Loss of the histone methyltransferase EZH2 induces resistance to multiple drugs in acute myeloid leukemia.Evaluation of BM cytomorphology after allo-SCT in patients with AML.Effect of postremission therapy before reduced-intensity conditioning allogeneic transplantation for acute myeloid leukemia in first complete remission.Association of a cytarabine chemosensitivity related gene expression signature with survival in cytogenetically normal acute myeloid leukemia.Data quality in the Danish National Acute Leukemia Registry: a hematological data resourceAddition of gemtuzumab ozogamicin to induction chemotherapy in adult patients with acute myeloid leukaemia: a meta-analysis of individual patient data from randomised controlled trials.Dual epigenetic targeting with panobinostat and azacitidine in acute myeloid leukemia and high-risk myelodysplastic syndromeLevel of RUNX1 activity is critical for leukemic predisposition but not for thrombocytopenia.Phase I/II study of the hypoxia-activated prodrug PR104 in refractory/relapsed acute myeloid leukemia and acute lymphoblastic leukemia.Complex karyotype, older age, and reduced first-line dose intensity determine poor survival in core binding factor acute myeloid leukemia patients with long-term follow-up.Prior cytopenia predicts worse clinical outcome in acute myeloid leukemia.Influence of cytarabine metabolic pathway polymorphisms in acute myeloid leukemia induction treatment.Global Cell Proteome Profiling, Phospho-signaling and Quantitative Proteomics for Identification of New Biomarkers in Acute Myeloid Leukemia Patients
P2860
Q24186270-9E6B2498-E302-4704-BB37-E2A5BE942E8CQ24186284-3DD463B8-3D9E-4B87-9525-0279A2A4715DQ24234645-E06F71BE-3D5F-42FB-B4A4-926C45B43AC2Q24234680-3AE15649-403F-44F9-9EF0-50F16D3CDD1FQ26765858-8FF3B021-EC5A-460B-A4F8-B2AFF0C57968Q26768260-BF11C7E8-71E9-4E7C-A6AF-EFCDA8E84BE2Q26770394-AFDC93BF-57F7-40FB-886E-2157E40899A2Q26771438-DFC0C2C8-6B1E-4105-ABDD-4FCA49A5B173Q26776393-496EDC1F-D1E8-4E68-884C-DA2F923482ABQ26991440-1090B12C-1982-40E9-BC1D-7B21526BC6E9Q26992280-8BE90362-EC37-4721-9261-6AEDF2D397F2Q27014126-5BA69EC8-9DD1-485F-924E-F898662DD628Q27021548-6665404A-8F94-4499-83A6-E20D47C9AB27Q27024006-FBE5C945-F5F1-4761-93E8-FB278178AB42Q27693865-FFA41D60-5EB7-4F0B-A95D-9364C35DB105Q27851686-277D7D96-7486-401E-B6F3-7075B5A80054Q27851713-6C1D6F94-C80C-412D-8EA4-C6FA56A9966DQ27851909-12C88B96-8A49-4149-AB1D-DB4E66D314CDQ27853004-55D0256D-9822-45FE-8681-E37695E720B8Q27853094-6D456322-49A3-43F5-A888-07372A4B59F0Q27853389-2008D7D4-C6CD-492E-9742-D9D640FDF428Q28078654-39D07EB9-3E05-4D1C-B321-C72E77402715Q28274561-F634B3E7-254E-4912-86FF-C940EDA323EFQ28547458-1D1EB260-CAB1-4BEF-BAD3-D8D855C8CB4CQ28602934-549072AE-4E89-41EB-9F94-BF9825BE9467Q30238679-26B2F729-59F5-44B2-886A-82CE9F9F9A05Q30252938-68CD0950-BC24-418A-B0DA-A284E43AEFC1Q30313615-22E9AD53-0C46-40A4-AD77-52351D4EB409Q30318110-14A6962E-E6E7-40E3-9514-D6EE53A36390Q30408294-CE589008-F1AD-4D06-A523-2248FB84D0F2Q30490446-3D1FB52C-A2F3-41FB-BDB8-EEC454E167A7Q30667157-AEB7360A-1811-40F1-82B2-1C25C27652DBQ30835785-3573B0D2-1F96-480E-8CDC-A8812E68AA01Q33163717-99E3EA88-B121-4688-88CA-EDDBEBEFDDCFQ33419236-09FF660A-84F8-4975-8813-0DB7B5AB1051Q33420436-AB702FED-38AD-4A5E-AEBD-943058827E2AQ33421005-6943AFDE-3B60-4D6D-8E7D-209447E9BA91Q33424807-FA25496F-0E58-4B78-9704-501437722497Q33442358-6CFFEB79-572B-411C-9BCE-0196C2A4A947Q33555287-D991AD43-93C0-4D41-AE71-E0F424F037A2
P2860
Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年学术文章
@wuu
2010年学术文章
@zh
2010年学术文章
@zh-cn
2010年学术文章
@zh-hans
2010年学术文章
@zh-my
2010年学术文章
@zh-sg
2010年學術文章
@yue
2010年學術文章
@zh-hant
name
Refinement of cytogenetic clas ...... dical Research Council trials.
@en
Refinement of cytogenetic clas ...... dical Research Council trials.
@nl
type
label
Refinement of cytogenetic clas ...... dical Research Council trials.
@en
Refinement of cytogenetic clas ...... dical Research Council trials.
@nl
prefLabel
Refinement of cytogenetic clas ...... dical Research Council trials.
@en
Refinement of cytogenetic clas ...... dical Research Council trials.
@nl
P2093
P50
P1433
P1476
Refinement of cytogenetic clas ...... edical Research Council trials
@en
P2093
Alan K Burnett
Anthony H Goldstone
David Grimwade
Helen Walker
Keith Wheatley
National Cancer Research Institute Adult Leukaemia Working Group
Stephen Chatters
P304
P356
10.1182/BLOOD-2009-11-254441
P407
P577
2010-04-12T00:00:00Z